Dec 13 (Reuters) - Helix Biopharma Corp
* Helix Biopharma Corp- Considers securing additional funds, expected to be through issuance of equity securities of company, to be of utmost importance
* Helix Biopharma - Cash reserves as at Oct 31, 2016, are insufficient to see current research and development initiatives through to completion.
* Helix Biopharma Corp. announces fiscal first quarter 2017 results
* Q1 loss per share C$0.04
Source text for Eikon:
Further company coverage: